CompletedPhase 2NCT02512588
A Study of Safety and Efficacy of BTD-001 in Treatment of Patients With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2
Studying Idiopathic hypersomnia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Balance Therapeutics
- Principal Investigator
- Lyndon Lien, PhDBalance Therapeutics, Inc.
- Intervention
- BTD-001(drug)
- Enrollment
- 120 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2015 – 2018
Study locations (23)
- Sleep Disorders Center of Alabama, Birmingham, Alabama, United States
- Stanford Medicine Sleep Center, Palo Alto, California, United States
- Pacific Research Network, San Diego, California, United States
- Empire Clinical Research, Upland, California, United States
- REM Sleep Medicine, Colorado Sleep Institute, Boulder, Colorado, United States
- PAB Clinical Research, Brandon, Florida, United States
- Clinical Research Group of St. Petersburg, St. Petersburg, Florida, United States
- Emory University School of Medicine Emory Sleep Center, Atlanta, Georgia, United States
- NeuroTrials Research Inc, Atlanta, Georgia, United States
- SleepMed of Central, Macon, Georgia, United States
- Kentucky Research Group,, Louisville, Kentucky, United States
- The Center for Sleep and Wake Disorders, Chevy Chase, Maryland, United States
- NeuroCare Center for Sleep, Newton, Massachusetts, United States
- Neurological Associate, Maplewood, Minnesota, United States
- Clayton Sleep Institute, St Louis, Missouri, United States
- +8 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02512588 on ClinicalTrials.govOther trials for Idiopathic hypersomnia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07500090A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH)Harmony Biosciences Management, Inc.
- RECRUITINGNCT06732284Study of Sleep Inertia in Major Depressive Disorder by the Psychomotor Vigilance TaskCentre Hospitalier Universitaire de Nīmes
- RECRUITINGPHASE2NCT07096674A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic HypersomniaCentessa Pharmaceuticals (UK) Limited
- RECRUITINGNANCT07006233A Novel Approach to Manage Symptoms of Narcolepsy and Idiopathic HypersomniaUniversity of Sydney
- RECRUITINGPHASE2NCT06843590A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic HypersomniaAlkermes, Inc.
- RECRUITINGPHASE2NCT06812078A Study of TAK-360 in Adults With Idiopathic HypersomniaTakeda
- RECRUITINGPHASE2, PHASE3NCT06767683A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic HypersomniaAlkermes, Inc.
- RECRUITINGPHASE2NCT06752668A Study of ORX750 in Participants With Narcolepsy and Idiopathic HypersomniaCentessa Pharmaceuticals (UK) Limited